Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung

European Journal of Cancer

Volumn 44, Issue 2, 2008, Pages 224-227

  Stanford, J L ^a   Stanford, C A ^a   O'Brien, M E R ^b   Grange, J M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Adenocarcinoma; Immunotherapy; Lung; Mycobacterium vaccae

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC AGENT; SRL 172; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INJECTION SITE REACTION; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM VACCAE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 38149032470     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.08.021     Document Type: Article

References (8)

1. Grange J.M., Stanford J.L., and Stanford C.A. Campbell De Morgan's 'Observations on cancer' and their relevance today. J Roy Soc Med 95 (2002) 296-299
2. Coley W.B. The treatment of inoperable malignant tumour with the toxins of erysipelas and Bacillus prodigiosus. Trans Am Surg Assoc 12 (1894) 183-196
3. Pearl R. Cancer and tuberculosis. Am J Hyg 9 (1929) 97-162
4. Krone B., Kölmel K.F., Henz B.M., and Grange J.M. Protection against melanoma by vaccination with Bacille Calmette-Guérin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 41 (2005) 104-117
5. O'Brien M.E., Anderson H., Kaukel E., et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 15 (2004) 906-914
6. Fayers P, Aaronson N, Bjordal K, Groenwold M, Curran D, Bottomley A. On behalf of EORTC Quality of Life Study Group. EORTC QLQ-C30 scoring manual.
7. Schmoor C. On problems related to subgroup analyses in clinical trials. Onkologie 23 (2000) 346-351
8. Grange J.M., Hobohm U., Bottasso O., Stanford C.A., and Stanford J.L. The role and rationale of adjuvant-based agents including heat-killed Mycobacterium vaccae for the immunotherapy of cancer. Eur J Cancer (2007) [this issue]